论文部分内容阅读
目的建立SD大鼠血浆中丹酚酸B含量的测定方法,观察丹酚酸B磷脂化后生物药剂学性质的改变。方法将随机分组的SD大鼠分别灌胃给丹酚酸B及丹酚酸B磷脂复合物药液,剂量2 g.kg-1,HPLC测定不同时间间隔的血药浓度,运用DAS1.0药动学程序计算药动学参数。结果丹酚酸B与丹酚酸B磷脂复合物给SD大鼠口服后在大鼠体内均为单室开放模型,丹酚酸B口服的AUC、ρmax、tmax分别为(46.044±11.341)μg.h.mL-1,(11.35±2.078)μg.mL-1,(0.642±0.113)h,而丹酚酸B磷脂复合物口服的AUC、ρmax、tmax分别为(74.959±17.493)μg.h.mL-1,(17.94±2.541)μg.mL-1,(0.887±0.176)h,丹酚酸B磷脂复合物的相对生物利用度为162.80%。结论丹酚酸B磷脂化后口服生物利用度提高,生物药剂学性质改善。
Objective To establish a method for the determination of salvianolic acid B content in plasma of SD rats, and to observe the changes of the biological properties after salvianolic acid B phospholipidization. Methods SD rats randomly assigned to receive salvianolic acid B and salvianolic acid B phospholipid complex solution, a dose of 2 g.kg-1, HPLC determination of plasma concentrations at different time intervals, the use of DAS1.0 drugs Kinematics program to calculate pharmacokinetic parameters. Results After oral administration of salvianolic acid B and salvianolic acid B phospholipid complex to SD rats, all the rats were single-compartment open model. The oral administration of salvianolic acid B had AUC, ρmax and tmax of (46.044 ± 11.341) μg, respectively. (11.35 ± 2.078) μg.mL-1, (0.642 ± 0.113) h, while the AUC, ρmax and tmax of salvianolic acid B phospholipid complex were (74.959 ± 17.493) μg.h orally, respectively. mL (-1), (17.94 ± 2.541) μg.mL-1, (0.887 ± 0.176) h. The relative bioavailability of salvianolic acid B phospholipid complex was 162.80%. Conclusion The oral bioavailability of Salvianolic acid B after phospholipidation is improved, and the biopharmaceutical properties are improved.